Document is current
Any future updates will be listed below
-
Authors
Hosseini-Gerami, Layla
Ficulle, Elena
Humphryes-Kirilov, Neil
Airey, David C.
Scherschel, James
Kananathan, Sarubini
Eastwood, Brian J.
Bose, Suchira
Collier, David A.
Laing, Emma
Evans, David
Broughton, Howard
Bender, Andreas
-
Funding
Funding for this research was provided by:
Biotechnology and Biological Sciences Research Council (BB/M011194/1, BB/M011194/1)
Eli Lilly and Company (BB/M011194/1, BB/M011194/1)
- License Information
-
More Information
Article History
Received: 13 September 2022
Accepted: 6 February 2023
First Online: 14 March 2023
Declarations
:
: All animal procedures were performed in accordance with the Animals (Scientific Procedures) Act 1986 and were reviewed by the internal Animal Welfare and Ethical Review Body (the Eli Lilly Animal Welfare Board) to ensure they comply with ethical and welfare standards. Procedures were in compliance with the ARRIVE guidelines. CBDD and MetaBase™ are proprietary to Clarivate™, who granted a license to Eli Lilly and Company for access and use. A license can be obtained by visiting . IPA is proprietary to QIAGEN, who granted a license to Eli Lilly and Company for access and use. A license can be obtained by visiting .
: Not applicable.
: SK, EF, NHK, JS, DA, BE, SB, DC, EL, DE and HB are either employees of Eli Lilly and Company or were employees during the time that this project was undertaken.
